Document Detail


How I treat hypereosinophilic syndromes.
MedLine Citation:
PMID:  19692700     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Hypereosinophilic syndromes (HESs) are a heterogeneous group of uncommon disorders characterized by marked peripheral eosinophilia and end organ manifestations attributable to the eosinophilia or unexplained in the clinical setting. Whereas corticosteroids remain the mainstay of treatment for most patients, recent diagnostic advances and the development of novel targeted therapies, including tyrosine kinase inhibitors and humanized monoclonal antibodies, have increased the complexity of therapeutic decisions in HESs. This review presents a treatment-based approach to the diagnosis and classification of patients with peripheral blood eosinophilia of 1.5 x 10(9)/L (1500/mm3) or higher and discusses the role of currently available therapeutic agents in the treatment of these patients.
Authors:
Amy D Klion
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Intramural; Review     Date:  2009-08-19
Journal Detail:
Title:  Blood     Volume:  114     ISSN:  1528-0020     ISO Abbreviation:  Blood     Publication Date:  2009 Oct 
Date Detail:
Created Date:  2009-10-30     Completed Date:  2009-11-17     Revised Date:  2013-05-31    
Medline Journal Info:
Nlm Unique ID:  7603509     Medline TA:  Blood     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3736-41     Citation Subset:  AIM; IM    
Affiliation:
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. aklion@niaid.nih.gov
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenal Cortex Hormones / therapeutic use*
Antibodies, Monoclonal / therapeutic use*
Humans
Hypereosinophilic Syndrome / blood*,  classification,  diagnosis*,  drug therapy*
Protein Kinase Inhibitors / therapeutic use*
Chemical
Reg. No./Substance:
0/Adrenal Cortex Hormones; 0/Antibodies, Monoclonal; 0/Protein Kinase Inhibitors
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Diacetylmorphine versus methadone for the treatment of opioid addiction.
Next Document:  Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked...